ALKERMES | ALKS - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 42.1B 1.19B 2026-03
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
ALKERMES USD 599.5M 56.06M 2026-03
Amgen USD 24.96B 534M 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Coherus Biosciences USD 140.39M 231.91M 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Gilead Sciences USD 9.48B 2.34B 2026-03
Heron Therapeutics USD 90.52M 5.58M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
J&J USD 57.72B 3.59B 2026-03
Malin Corporation EUR 1000K 500K 2024-12
Merck USD 26.94B 1.38B 2026-03
Minerva Neurosciences USD 2.29M 381K 2025-12
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Otsuka Holdings JPY 686.12B 63B 2026-03
Ovoca Bio EUR 186K 2.26M 2025-06
Pfizer USD 34.35B 2.64B 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03